Aligos Therapeutics Inc (ALGS) Stock Price, Quote & News

Company Profile

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-12575...

Industry: Biotechnology

Sector: Healthcare

Phone: 800 466 6059

Website: www.aligos.com

Address:

One Corporate Drive, 2nd Floor, South San Francisco, United States

Bwnuts Dec. 24 at 3:16 PM

$ALGS I wonder why management and board aren’t buying shares? Seems they know better. This is the white collar version of $VMAR So long as someone is willing to give them cash, management can continue taking their fat salaries. That’s literally the game here. They stopped caring about the stock price $36 ago. When is the last time anyone heard from the CEO? I’ll wait.

1 · Reply

SignalVampire7 Dec. 24 at 2:51 PM

$ALGS thin small cap barely moves asymmetry high but risk elevated

1 · Reply

Suppandi Dec. 24 at 2:20 PM

$ALGS This stock as PT of $175. Will we see that anytime soon

1 · Reply

SwissAccount Dec. 24 at 12:44 PM

$ALGS Sentiment could pivot sharply depending on how progress validates the underlying thesis beyond narrative appeal. Execution slippage remains the dominant downside risk.

1 · Reply

Bwnuts Dec. 23 at 8:00 PM

All newly granted options must immediately go red. It's the $ALGS way.

0 · Reply

Bwnuts Dec. 23 at 5:31 PM

$ALGS wonder how these board meetings go? Do they even meet? Meeting starts at 5pm, shake hands, look at the one page deck, head to dinner.

0 · Reply

Bwnuts Dec. 23 at 4:16 PM

$ALGS haha. Now #1

1 · Reply

MysticGlide Dec. 21 at 4:19 PM

$ALGS decent close

0 · Reply

Bwnuts Dec. 18 at 7:50 PM

$ALGS 200EMA was resistance. Will it flip to support? Of course it won’t. That’s not the $ALGS way. Does anyone wonder why this thing never performs? It burns every technical trader that tries to trade it and then they never touch it again. Been going on for years.

0 · Reply

Lynx12 Dec. 18 at 4:19 PM

$ALGS damn I'm all in on this and hope it going to 20+ again.

1 · Reply

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 11, 2025, 8:00 AM EST - 14 days ago

Aligos Therapeutics Presents Positive Data at HEP-DART 2025

Nov 20, 2025, 7:43 PM EST - 4 weeks ago

Aligos Therapeutics, Inc. (ALGS) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 10, 2025, 8:00 AM EST - 6 weeks ago

Aligos Therapeutics Presents Positive Data at The Liver Meeting® 2025

Nov 6, 2025, 8:30 AM EST - 7 weeks ago

Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results

Nov 4, 2025, 8:30 AM EST - 7 weeks ago

Aligos Therapeutics to Present at Upcoming Investor Conferences

Oct 30, 2025, 8:30 AM EDT - 2 months ago

Aligos Therapeutics to Announce 3rd Quarter 2025 Financial Results on November 6, 2025

Oct 16, 2025, 8:30 AM EDT - 2 months ago

Aligos Therapeutics Receives USAN Council Approval for pevifoscorvir sodium as Nonproprietary Name for ALG-000184

Oct 14, 2025, 8:30 AM EDT - 2 months ago

Aligos Therapeutics to Present at the H.C. Wainwright Liver Disease Conference

Oct 7, 2025, 8:30 AM EDT - 2 months ago

Aligos Therapeutics Announces Eight Abstracts Accepted at The Liver Meeting® 2025

Sep 3, 2025, 4:05 PM EDT - 4 months ago

Aligos Therapeutics Announces Six Preclinical Presentations at the 2025 International HBV Meeting

Sep 2, 2025, 4:05 PM EDT - 4 months ago

Aligos Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 20, 2025, 8:30 AM EDT - 4 months ago

Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Ramón Polo as Senior Vice President, Head of Global Regulatory Affairs

Aug 13, 2025, 8:30 AM EDT - 4 months ago

Aligos Therapeutics Announces First Subject Dosed in the Phase 2 B-SUPREME Study of ALG-000184 in Subjects with Chronic HBV Infection

Aug 6, 2025, 4:05 PM EDT - 5 months ago

Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results

Jul 30, 2025, 4:05 PM EDT - 5 months ago

Aligos Therapeutics to Announce 2nd Quarter 2025 Financial Results on August 6, 2025

Jun 18, 2025, 8:00 AM EDT - 6 months ago

Aligos Therapeutics Appoints Kieron Wesson as Vice President, Head of Chemistry Manufacturing Controls (CMC)

May 29, 2025, 8:00 AM EDT - 7 months ago

Aligos Therapeutics to Present at the Jefferies Global Healthcare Conference

May 20, 2025, 8:00 AM EDT - 7 months ago

Aligos Therapeutics Appoints Laura Kavanaugh as Vice President, Head of Legal

May 8, 2025, 8:00 AM EDT - 8 months ago

Aligos Therapeutics Presents Positive Data at the EASL Congress 2025

May 6, 2025, 8:00 AM EDT - 8 months ago

Aligos Therapeutics Reports Recent Business Progress and First Quarter 2025 Financial Results

Apr 29, 2025, 8:30 AM EDT - 8 months ago

Aligos Therapeutics to Announce 1st Quarter 2025 Financial Results on May 6, 2025

Apr 23, 2025, 4:05 PM EDT - 8 months ago

Aligos Therapeutics Announces Eight Abstracts Accepted for Presentation at the EASL Congress 2025

Mar 26, 2025, 8:00 AM EDT - 9 months ago

Aligos Therapeutics Presents Positive Data at APASL 2025

Mar 10, 2025, 8:00 AM EDT - 10 months ago

Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results

Mar 3, 2025, 8:00 AM EST - 10 months ago

Aligos Therapeutics to Announce 4th Quarter 2024 Financial Results on March 10, 2025

Feb 12, 2025, 7:00 AM EST - 11 months ago

Aligos Therapeutics Announces $105 Million Private Placement Financing

Nov 19, 2024, 1:30 PM EST - 1 year ago

Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024

Nov 6, 2024, 4:05 PM EST - 1 year ago

Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results

Oct 1, 2024, 8:00 AM EDT - 1 year ago

Aligos Therapeutics Appoints David Perry as Vice President of Business Development

Sep 30, 2024, 8:00 AM EDT - 1 year ago

Aligos Therapeutics to Present at Investor Conferences in October

Sep 19, 2024, 8:00 AM EDT - 1 year ago

Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH

Sep 18, 2024, 5:00 PM EDT - 1 year ago

Aligos Therapeutics to Announce Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH on September 19, 2024

Aug 15, 2024, 9:00 AM EDT - 1 year ago

Aligos Therapeutics Announces Reverse Stock Split

Aug 8, 2024, 4:05 PM EDT - 1 year ago

Aligos Therapeutics Strengthens Board with Two New Independent Directors

Jul 22, 2024, 9:00 AM EDT - 1 year ago

Aligos Therapeutics Announces Clinical Collaboration with Xiamen Amoytop Biotech Co., Ltd.

Jul 10, 2024, 8:00 AM EDT - 1 year ago

Aligos Therapeutics to Host KOL Event to Discuss the Positive Phase 1b Data from ALG-000184 for the Treatment of CHB

Jun 5, 2024, 2:30 AM EDT - 1 year ago

Aligos Therapeutics Presents Positive Data at the EASL Congress 2024

May 22, 2024, 4:05 PM EDT - 1 year ago

Aligos Therapeutics Announces Six Abstracts Accepted for Presentation at EASL 2024

May 21, 2024, 8:00 AM EDT - 1 year ago

Aligos Therapeutics Announces the Completion of Enrollment in the ALG-055009 Phase 2a HERALD Study for the Treatment of MASH

Apr 30, 2024, 4:05 PM EDT - 1 year ago

Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024

Apr 25, 2024, 4:05 PM EDT - 1 year ago

Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study

Mar 27, 2024, 8:00 AM EDT - 1 year ago

Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies

Mar 12, 2024, 4:05 PM EDT - 1 year ago

Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results

Mar 5, 2024, 4:05 PM EST - 1 year ago

Aligos Therapeutics to Announce 4th Quarter 2023 Financial Results on March 12, 2024

Feb 26, 2024, 8:00 AM EST - 1 year ago

Aligos Therapeutics To Participate in the Leerink Partners Global Biopharma Conference 2024

Feb 20, 2024, 8:00 AM EST - 2 years ago

Aligos Therapeutics to Host KOL Event to Discuss Phase 2a HERALD Study of ALG-055009 in MASH on March 7, 2024

Dec 7, 2023, 4:05 PM EST - 2 years ago

Aligos Therapeutics Presents Positive Clinical Data at Hep-DART 2023 from Phase 1 Studies in HBV (ALG-000184) and NASH (ALG-055009)

Nov 20, 2023, 4:05 PM EST - 2 years ago

Aligos Therapeutics To Present at the Piper Sandler Healthcare Conference

Nov 13, 2023, 8:00 AM EST - 2 years ago

Aligos Therapeutics Presents Clinical and Nonclinical Data at the AASLD Liver Meeting® 2023 Demonstrating that ALG-055009 has a Favorable Risk-Benefit Profile

Bwnuts Dec. 24 at 3:16 PM

1 · Reply

SignalVampire7 Dec. 24 at 2:51 PM

$ALGS thin small cap barely moves asymmetry high but risk elevated

1 · Reply

Suppandi Dec. 24 at 2:20 PM

$ALGS This stock as PT of $175. Will we see that anytime soon

1 · Reply

SwissAccount Dec. 24 at 12:44 PM

$ALGS Sentiment could pivot sharply depending on how progress validates the underlying thesis beyond narrative appeal. Execution slippage remains the dominant downside risk.

1 · Reply

Bwnuts Dec. 23 at 8:00 PM

All newly granted options must immediately go red. It's the $ALGS way.

0 · Reply

Bwnuts Dec. 23 at 5:31 PM

$ALGS wonder how these board meetings go? Do they even meet? Meeting starts at 5pm, shake hands, look at the one page deck, head to dinner.

0 · Reply

Bwnuts Dec. 23 at 4:16 PM

$ALGS haha. Now #1

1 · Reply

MysticGlide Dec. 21 at 4:19 PM

$ALGS decent close

0 · Reply

Bwnuts Dec. 18 at 7:50 PM

0 · Reply

Lynx12 Dec. 18 at 4:19 PM

$ALGS damn I'm all in on this and hope it going to 20+ again.

1 · Reply

Bwnuts Dec. 18 at 3:30 AM

$ALGS can’t give the new people equity at a 70% discount to the last grants. Have to pump it to higher prices to prevent the older workforce from revolting. In normal companies this isn’t much of an issue because stock price generally goes up over time. NOT HERE.

0 · Reply

Bwnuts Dec. 16 at 4:32 PM

$ALGS it’s just coincidence that the stock pumps to grant equity then immediately comes right back to where it started from. Happens every time.

0 · Reply

Lynx12 Dec. 16 at 4:05 PM

$ALGS anyhope for this stock.

0 · Reply

Tray731 Dec. 14 at 11:47 PM

$ALGS https://www.stocktitan.net/news/ALGS/aligos-therapeutics-presents-positive-data-at-hep-dart-rznjkeumypw6.html

0 · Reply

Tray731 Dec. 14 at 11:17 PM

$ALGS have over 2000 shares in this stock! not planning on selling a single stock! very low short interest too!!

0 · Reply

IPOARMY1 Dec. 13 at 11:16 PM

$ALGS @Bwnuts not anymore

1 · Reply

StockScanners Dec. 13 at 8:03 PM

$ALGS keep watch if this holds above 12.30

0 · Reply

Teeemo16 Dec. 12 at 3:58 PM

$ALGS Breaking out with volume

0 · Reply

Dieseld28 Dec. 12 at 3:26 PM

$RYM $ALGS

0 · Reply

Dieseld28 Dec. 12 at 3:23 PM

$ALGS Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://finance.yahoo.com/news/aligos-therapeutics-announces-inducement-grants-130000787.html

0 · Reply

stockmet Dec. 12 at 3:15 PM

$ALGS alerted at $8…💰🤑🎁

0 · Reply

vasilp Dec. 12 at 2:15 PM

$ALGS wop, wop something is brewing here ! Piper Sandler raised target to 175$ https://www.tipranks.com/news/blurbs/piper-sandler-reaffirms-their-buy-rating-on-aligos-therapeutics-algs-blurbs

0 · Reply

Market Cap	61.23M
Revenue (ttm)	3.95M
Net Income (ttm)	-131.21M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-3,321.77%
Debt to Equity Ratio	0.00

Volume	45,900
Avg Vol	84,176
Day's Range	N/A - N/A
Shares Out	6.15M
Stochastic %K	18%
Beta	2.74
Analysts	Strong Sell
Price Target	$95.00